Investigational Medicinal Product Dossiers, IMPD submissions, QP, GMP, EMA

Freyr assist pharma manufacturers in IMPD submission for innovator medicinal products, provides professional advice to appoint qualified person (QP) for Good Manufacturing Practices (GMP), supports in compilation and submission of updates/amendments to IMPDs.

An Investigational Medicinal Product (IMP) is a pharmaceutical form of an active substance which is to be tested / to be used as reference in a clinical trial. The Investigational Medicinal Product Dossier (IMPD) is a support document providing information on the quality, manufacturing and control of the IMP, non-clinical studies conducted with the IMP, clinical use of the IMP, and the overall risk / benefit assessment of the IMP in the proposed trial.

An IMPD is one of the essential documents that form the clinical trial application (CTA) submitted to competent authorities of EU member states for non-authorized IMPs. Where an IMP is subject of a marketing authorization, the Summary of Product Characteristics in addition to other necessary data can be submitted in lieu of the IMPD. The challenge lies with conducting clinical trials in multiple member states, trial execution in multiple sites and subsequent reporting/updates to IMPD.

Hands on experience in EU Regulatory submissions and handling IMPD applications will help in optimal planning of Regulatory submission and smooth execution of trial related logistics for complex clinical programs. Also, with the proposed implementation of new clinical trial regulation 536/2014 expected to be effective in 2019, the way clinical trials are conducted in the EU is expected to undergo a major change. Compilation of different phases of IMPDs in compliance with EU-specific Regulatory requirements and managing the Regulatory hurdles for different types of products (New molecular entity, precision therapy medicines, recombinant protein products, vaccines, stem cell-based products etc.) require proven Regulatory expertise.

Know more at Freyr Page - Investigational Medicinal Product Dossiers (IMPD) submissions

Comments

Post a Comment

Popular posts from this blog

Medical Device Regulation Report, Morocco, Registration

This report provides information on regulations imposed on medical device in Morocco for product registration, import permit, validity & renewal process, variations filing, legal representative and labeling. Summary Product definition and governing regulations; Information on medical device registration; Explains the process of registration through flowcharts; Precise information on health authority fees & timelines for registration; Additional information on the validity of registration, renewal process and variation filing Presents the regulations applicable on labeling; and Describes the information on import regulations, and the requirement of a legal representative. Check out more details at  Medical Device Regulation Report, Morocco, Registration
Read more

Medical Device Registration in Germany, IVDs, CE marking, EU MDR

Freyr offer Regulatory services for Medical Device & IVDs that includes registration with EMA, licensing, EU-MDR Transition, Classification, Dossier Review, Compilation & Submission, CE mark & ISO 13485 certification, provides support to certify medical devices from TUV, DQS, DEKRA, SGS in Germany region – Freyr Webpage Link – Medical Device Registration in Germany Freyr Expertise European Medical Device Classification ISO 13485 Compliance CE Technical File or Design Dossier Review, Compilation and Submission EU-MDR Transition and Support Clinical Evaluation Reports (CER) for Medical Devices ISO 14971 Risk Management Consulting Medical Device Regulatory Strategy Report Testing Support- Biocompatibility, Electrical Safety and Mechanical & Performance Labeling and GMP Support Post-market Monitoring and Adverse Event Reporting European Authorized Representative Support
Read more

Health Authority Queries – Responses | Interactions

The appropriate and timely communication with Health Authorities (HAs) is a key factor for the speedy approval and uninterrupted commercialization of a medicinal product either during initial approval or during Life Cycle Management (LCM, i.e. through post approval changes submissions). When a  Marketing Authorization Holder (MAH)  or applicant submits an initial or post approval activity application, upon evaluating the submitted data HAs may revert with their concerns or recommendations, if the submitted data is insufficient or requires any further clarification or for any further commitments post approval to ensure quality, safety and efficacy of the product. Either the Information Requests (IRs), Refuse to Review (RTR), or Request for Further Information (RFI), the expertise lies in understanding the concerns, response compilation while answering, so that it avoids further queries and delays in the approval procedures. While responding to HA queries, the communication ...
Read more